Thus, Hassan and colleagues previously showed that serum mesothelin is detectable in patients with mesothelioma or in serum, from patients with ovarian cancer at a significantly higher median concentration as compared to serum from healthy donors [17]. This evidence concerns the gene MSLN and ovarian cancer.